Field Safety Notice

SBN-CPS-2016-002

CPS / TDM
Version 1
21-APR-2016

Digitoxin (CC) Lot-Lot Variances Based on Change of Raw Material

Product Name	Digitoxin
Product Description	Cat# 03374670190: HITACHI DIGITOXIN (911,912,917,P) Cat# 20753599 322: DIGITOXIN, 200Tests, cobas c, Integra Cat# 05841283 190: ONLINE TDM Digitoxin 200 tests, c 701,702
GMMI / Part No **Device Identifier**	Cat# 03374670190 Cat# 20753599 322 Cat# 05841283 190
Production Identifier (Lot No./Serial No.)	**HITACHI DIGITOXIN (911,912,917,P)** Lot 72199322 **DIGITOXIN, 200Tests, cobas c, Integra** Lot 11968401, Lot 61304301, Lot 61598601 **ONLINE TDM Digitoxin 200 tests, c701,702** Lot 61304001, Lot 61598301
SW Version	n/a
Type of Action	Field Safety Corrective Action (FSCA)

Affected lots are not available in Singapore

Dear Valued Customer,

Description of Situation

We received one complaint from a customer observing a strong scattering of patient sample results. Investigations have identified a changed antibody specificity as the major root cause of the observed issues. For digoxin and digoxin like drugs the cross reactivity was found to be significantly increased (approximately 200% cross reactivity for digoxin) which means that for approximately 1ng/mL digoxin present in the sample the digitoxin result is elevated by approximately 2ng/mL.
Based on these findings, the ONLINE TDM Digitoxin test does not meet the specifications anymore and cannot be brought back within a short time. As a consequence and to our regret, we have to inform you that the further distribution of all ONLINE TDM Digitoxin lots for **MODULAR** *ANALYTICS* <P>, **cobas c** and COBAS INTEGRA systems have stopped.

Roche Diagnostics Asia Pacific Pte Ltd
8 Kallang Avenue
#10-01/09 Aperia Tower 1
Singapore 339509
Tel. +65 – 6272 7500
Fax +65 – 6371 6633

Digitoxin (CC) Lot-Lot Variances Based on Change of Raw Material

The following products and lots are affected:

Cat.-Number	Product kit name	Lot number	End of shelf life
03374670190	HITACHI DIGITOXIN (911,912,917,P)	72199322	31st March 2017
20753599322	DIGITOXIN, 200Tests, cobas c, Integra	11968401	28th February 2017
		61304301	31st May 2016
		61598601	31st August 2016
05841283190	ONLINE TDM Digitoxin 200 tests, c701,702	61304001	31st May 2016
		61598301	31st August 2016

In rare cases, erroneous digitoxin results or implausible combination of results in patient with previously or simultaneously administered digoxin may occur, particularly if the drug containing digitalis is unknown and a medical risk for the patients cannot be entirely excluded.

The way samples may be affected due to cross reactivity with digoxin is based on different therapy scenarios, which are shown exemplarily below:

1. Patient(s) undergoing mono-therapy with digoxin:
   - Testing of digitoxin and digoxin from the same sample: The digoxin result should be accurate and match clinical symptoms. The digitoxin results could be falsely positive showing at max. low levels within the therapeutic range. As it is very unlikely that a patient would be treated with digoxin and digitoxin, the result would be implausible.
   - If digitoxin would be tested solely, the level would be false positive, but below measuring range for digitoxin unless a very high dosage of digoxin was administered.,
   - If digoxin would be tested solely, no medical risk is related.

2. Patient(s) undergoing mono-therapy with digitoxin:
   - At the upper end of therapeutic ranges of digitoxin a false low result may lead to underestimation of digitoxin levels in a subset of approximately 10 – 20% of the samples. If in these cases the issue would lead to an increase of dosage a subsequent overdosage cannot entirely be excluded.

3. Patient(s) undergoing therapy with digitoxin and digoxin/digoxin like drugs:
It is very unlikely that a patient is treated with digoxin and digitoxin in parallel.

Roche Diagnostics
Asia Pacific Pte Ltd
8 Kallang Avenue
#10-01/09 Aperia Tower 1
Singapore 339509
Tel. +65 – 6272 7500
Fax +65 – 6371 6633

Digitoxin (CC) Lot-Lot Variances Based on Change of Raw Material

Actions taken by Roche Diagnostics

Products from the affected lots do not meet specifications anymore and a solution is not feasible within a short time. As a consequence we have decided to withdraw the ONLINE TDM Digitoxin assay used on **MODULAR** ***ANALYTICS*** <P>, **cobas c** 311 analyzer, **cobas c** 501/502 and **c** 701/702 modules and COBAS INTEGRA 400 plus and 800 immediately from the market, block the existing inventory of the affected lots and stop further distribution of the named products for the time being. Based on further analysis new antibody lots will be manufactured to re-establish the original specificity and to ensure the right quality and test performance in the near future. A timeline for a re-start of distribution will be communicated as soon as possible, current estimation is Q4/2016.

Actions to be taken by the customer/user

Please stop using the affected products and discard locally any remaining kits of the named ONLINE TDM Digitoxin products from your inventory and analyzers immediately. If possible please consider to use the Elecsys® Digitoxin assay (Cat.-No.: 03002659122) on **cobas e** module which is not affected by the described issue.

Communication of this Field Safety Notice (if appropriate)

This notice must be passed on to all those who need to be aware within your organization or to any organization/individual where the potentially affected test kits have been distributed/supplied.

Please transfer this notice to other organizations/individuals on which this action has an impact.

Please maintain awareness of this notice and resulting action for an appropriate period to ensure the effectiveness of the corrective action. The signature confirms that this notice has been notified to the appropriate Regulatory Agency.

Sincerely,

Roche Diagnostics Asia Pacific Pte Ltd
Email: sg.regulatory@roche.com